In B16 melanoma cells, cAMP-induced melanogenesis is inhibited by the tumor promoting phorbol ester, TPA. However, the role of PKC activation or depletion in the inhibition of melanogenesis by TPA remains controversial. In this report, using speci®c PKC inhibitors, we demonstrated that PKC inhibition does not impair cAMPinduced melanin synthesis and tyrosinase expression. Further, the inhibition of melanogenesis by TPA results from a decrease of the tyrosinase promoter transcriptional activity and this eect is mimicked by over-expression of a constitutively active form of PKC a. These ®ndings clearly demonstrate that PKC activation accounts for the inhibition of melanin synthesis by TPA. Additional experiments were undertaken to elucidate the mechanism by which TPA inhibits the tyrosinase gene transcription. Deletions and mutation in the tyrosinase promoter showed that TPA acts on a M-box which is involved in tissuespeci®c expression and regulation by cAMP of the tyrosinase gene. We showed that TPA decreases the binding of microphthalmia, a basic helix ± loop ± helix transcription factor, to the M-box. Since microphthalmia, strongly stimulates the transcriptional activity of the promoter we propose that TPA, through PKC activation, decreases microphthalmia binding to the M-box of the tyrosinase promoter, thereby leading to a reduced tyrosinase expression and melanogenesis inhibition.
Introduction
In mammals, melanins are responsible of skin and hair color. These pigments are synthesized in highly specialized cells, the melanocytes, found in the basal layer of the epidermis (Le Douarin, 1982) . Three enzymes: tyrosinase, tyrosinase related protein 1 (TRP1) and tyrosinase related protein 2 (TRP2) are involved in this enzymatic process. These enzymes are restricted to melanocytes suggesting the existence of a tissue-speci®c regulatory mechanism which controls the transcription of their genes. A regulatory element, thought to be involved in the cell speci®c expression of the melanogenic enzymes, is conserved in the promoter of the three enzymes (Ganss et al., 1994; Lowings et al., 1992; Yokoyama et al., 1994a) . This element, called M-box, binds microphthalmia a transcription factor of the basic-helix ± loop ± helix-leucine-zipper family (b-HLH-LZ) which strongly transactivates tyrosinase and TRP1 promoter activities (Ganss et al., 1994; Lowings et al., 1992; Yavuzer et al., 1995) .
Tyrosinase catalyzes the conversion of tyrosine to DOPA and the oxidation of DOPA to DOPAquinone (Hearing and Jimenez, 1987; Hearing and Tsukamoto, 1991) . Then, TRP1 and TRP2 are involved in the processing of DOPAquinone to melanin polymers (Jackson et al., 1992; Kobayashi et al., 1994; Yokoyama et al., 1994b) . Since tyrosinase controls the ®rst and rate limiting step of melanogenesis, it is considered as the key enzyme of this cascade and the target of the dierent eectors which regulate melanin synthesis.
In humans, melanogenesis is principally stimulated by the ultraviolet B (U.V.B) radiation of the solar light (Aberdam et al., 1993; Friedmann et al., 1990) and melanins have been shown to play a key photoprotective role against the carcinogenic eects of U.V.B. radiation. In cultured cells, melanogenesis can be upregulated by a large array of stimuli among which cAMP elevating agents such as aMSH (Fuller and Viskochil, 1979; JimeÂ nez et al., 1988) , IBMX and forskolin are the most potent (Englaro et al., 1995; Hearing and Tsukamoto, 1991; Hunt et al., 1994; Wong and Pawelek, 1975) . Stimulation of melanogenesis by cAMP elevating agents mainly results from an augmentation of the tyrosine expression. Recently, the mechanism of cAMP action on the tyrosinase expression has been partially elucidated. Indeed, we have shown that cAMP increased the transcriptional activity of the tyrosinase promoter through the stimulation of microphthalmia binding to a M-box motif located upstream from the TATA-box (Bertolotto et al., 1996) .
In B16 mouse melanoma cells, melanogenesis is inhibited by the tumor promoting phorbol ester, TPA Fuller et al., 1990; Kuzumaki et al., 1993; Mahalingam et al., 1996) . The mechanism by which TPA exerts its eect remains controversial. TPA is a strong activator of classical PKC (a, b, g, s) . However, long exposures of cells to TPA lead to a depletion of certain PKC isoforms (Brooks et al., 1993; Oka et al., 1995) . Thus, it is not clear whether PKC activation or PKC depletion is responsible for melanogenesis inhibition.
Independently of the role of PKC activation or depletion, the eect of TPA on the melanogenic pathway has not been elucidated. At least two hypothesis can be considered. First, TPA would inhibit the tyrosinase activity or decrease the stability of this enzyme through a post-translational modi®cation. Secondly, TPA could decrease the transcription of the tyrosinase gene leading to a depletion of this enzyme.
In the present report, using speci®c PKC inhibitors and transfection with a constitutively active form of PKC a, we aimed to reassess the role of PKC activation and particularly that of PKC a in the inhibition of melanogenesis. Further, using a luciferase reporter gene driven by a 2.2 kb fragment of the tyrosinase promoter, we designed experiments to investigate the eect of TPA on the tyrosinase gene transcription and on the binding of the transcription factor, microphthalmia, that controls tyrosinase gene expression.
Results
Inhibition of PKC does not account for the inhibition of melanogenesis by TPA Initially, we investigated the eects of TPA and several PKC inhibitors on basal and cAMP-induced melanogenesis in B16-F10 mouse melanoma cells (Figure 1 ). We observed a strong stimulation of melanin synthesis after a 48 h treatment with forskolin (15-fold). TPA did not signi®cantly aect the basal level of melanins, but markedly reduced (60%) the melanin content in forskolin-treated cells. Interestingly, PKC inhibitors such as staurosporine, RO 8220 or RO 3282 signi®cantly increased the melanin content (respectively seven-, three and threefold). Further, RO 3282, a speci®c inhibitor of PKC a and b, did not impair the stimulation of melanogenesis evoked by forskolin.
The eect of these agents on tyrosinase expression was then studied. Western blot experiments using an anti-tyrosinase antibody (Figure 2) showed that forskolin markedly stimulated tyrosinase expression. TPA prevented partially the eect of forskolin. The PKC inhibitors increased tyrosinase expression and RO 3282 did not aect the stimulation of tyrosinase expression by forskolin. Under these conditions, tyrosinase was not expressed in basal state. However, on an over-exposed ®lm (not shown), a band corresponding to tyrosinase was observed in basal conditions, and TPA decreased slightly its expression.
These results indicate that the inhibition of melanogenesis by TPA results from a decrease in the tyrosinase expression. This eect appears to be mediated through PKC activation, since PKC inhibitors stimulate melanogenesis and do not prevent the stimulation of melanogenesis by forskolin.
TPA prevents the activation of the tyrosinase promoter induced by forskolin
To further investigate the mechanism by which TPA inhibits melanogenesis, we studied the eect of TPA on the mouse tyrosinase promoter activity. B16 cells were transiently transfected with pTYRO and exposed to forskolin and/or TPA for 48 h (Figure 3 ). While forskolin strongly stimulated the transcriptional activity of the tyrosinase promoter (17-fold), addition of TPA in the medium strongly reduced this stimulatory eect (sevenfold). The speci®c PKC a inhibitor, RO 3282, stimulated by itself the transcriptional activity of the tyrosinase promoter and did not reduce the stimulation induced by forskolin of the promoter.
To con®rm the eect of these pharmacological agents, we studied the tyrosinase promoter activity in cells overexpressing a constitutively active form of PKC a. As shown in Figure 4 , transient transfection of B16 cells with an expression vector encoding the active PKC a led to a marked decrease in the tyrosinase promoter activity induced by forskolin. We also observed a 50% inhibition of the basal activity. As a control, we showed that active PKC a did not signi®cantly impair the stimulation by forskolin of a CRE-luc reporter gene. Further, active PKC a stimulates (4 ± 5-fold) the transcriptional activity of the TRE-luc reported gene (not shown). These data show that the eect of TPA on melanogenesis correlates with the inhibition of the tyrosinase promoter activity. The eect of TPA has been mimicked by active PKC a thus demonstrating the key role of PKC activation in the inhibition of melanogenesis by TPA.
Inhibition by TPA of the tyrosinase promoter activity involves the M-box and microphthalmia Next, we wished to further investigate the eect of TPA on the transcriptional activity of the tyrosinase promoter. TPA has been described to activate AP1 transcription factor that binds to the TPA Responsive Element (TRE) TGA(C/G)TCA. Thus, we hypothesized that the AP1 complex induced by TPA could bind to the tyrosinase promoter and inhibit its activity. Three TRE-like sequences were found in the tyrosinase promoter at 72060, 71563 and 71480 base pairs upstream from the initiation start site. Hence, we studied the eect of TPA on three dierent tyrosinase promoter constructs. The ®rst one contained a 1.3 kb fragment of the promoter, pTYRO-1.3, in which the three TRE-like motifs had been deleted. The responsiveness to forskolin of this construct was identical to that of the initial pTYRO-2.2 and TPA markedly decreased the stimulation of its transcriptional activity by forskolin ( Figure 5) . A second construct, pTYRO-0.1, containing the minimal promoter fragment required for optimal tissue-speci®c expression and cAMP responsiveness was studied. As expected, this construct showed a full forskolin response which was inhibited by TPA. Careful examination of this promoter fragment revealed the presence of a TRE-like motif overlapping with the Mbox. Mutation of this TRE motif (pTYRO-0.1DAP1) did not signi®cantly impair either the response to forskolin or the inhibition of the promoter activity by TPA. Taken together, these results suggest that TPA acts on the same cis-acting elements that control the tissuespeci®c expression and the cAMP response. This regulatory element called M-box contains a core sequence CATGTG which binds microphthalmia, a melanocyte-speci®c transcription factor of the b-HLH family. Hence, we investigated the eect of TPA treatment on the microphthalmia binding to the Mbox in both basal and forskolin-treated cells ( Figure 6 ). B16 nuclear extracts formed complexes with the labeled M-box (lanes 1 and 2) which were greatly increased upon forskolin treatment (lanes 3 and 4). On the other hand, TPA strongly reduced the formation of M-box complexes in both basal (lane 6) and forskolin treated cells (lane 8). The complexes were almost totally and speci®cally displaced by microphthalmia antibody (lanes 2, 4, 6 and 8) thus indicating that in B16 melanoma cell nuclear extracts, the major M-box binding activity is microphthalmia. These results demonstrate that TPA decreases the binding of microphthalmia to the M-box.
Discussion
In the ®rst part of this report, we showed that TPA inhibits cAMP-induced melanin synthesis and tyrosinase expression. Using pharmacological inhibitors of PKC activity, we demonstrated that inhibition of PKC stimulates melanogenesis and does not prevent cAMP induced-tyrosinase expression or melanogen- esis. The eect of TPA on tyrosinase expression is mediated through a decrease in the tyrosinase gene transcription. A molecular approach, with a constitutively active form of PKC a, showed that PKC a activation leads to an inhibition of the transcriptional activity of the tyrosinase promoter. Hence, we concluded that the inhibition of melanogenesis by TPA is mediated by the activation of a PKC which might be the a isoform. However, some reports disagree with our observations. Indeed, PKC activation was reported to stimulate melanogenesis. In B16 melanoma cells, over-expression of PKC a after retinoic acid treatment or after stable transfection, increases pigmentation (Gruber et al., 1992 (Gruber et al., , 1995 Mahalingam et al., 1996) . The discrepancy between these results and ours can be explained by the selection of stable cell lines in reports of Gruber et al. Indeed, it is possible that long-term overexpression of PKC a modi®es greatly the general metabolism of the cells resulting in the selection of the most pigmented clones. In our experiments we used a transient transfection assay that allows to evaluate the acute eect of an increased PKC a activity.
Long-term treatment with TPA was reported to inhibit melanin synthesis in S91 mouse melanoma cell (Park et al., 1996) and this eect was ascribed to PKC depletion. However, it appears obvious that even after a long-term exposure, TPA should keep on acting to maintain PKC down-regulation. Thus, it is reasonable to propose that the inhibition of melanogenesis after a long-term exposure to TPA is mediated through a cryptic pool of PKC or a speci®c PKC isoform that is still activated at that time by TPA. This hypothesis is supported by recent data obtained in melanocytes, demonstrating that PKC z activity increases after 48 h of TPA treatment (Oka et al., 1995) .
On the other hand, long-term exposure to TPA of normal human melanocytes leads to an increased melanogenesis (Abdel-Malek et al., 1992) . This discrepancy could be explained by the use of TPA as mitogen for human melanocyte cultures that would probably result in a sustained PKC depletion and a commitment of melanocytes in the dierentiation program ending in melanogenesis stimulation (Stocker et al., 1991) . Moreover, several reports from Gilchrest group showed that PKC b isoform phosphorylates and activates tyrosinase thereby playing a key role in the regulation of melanogenesis (Park et al., 1993) . The lack of PKC b expression in B16 melanoma cells (Oka et al., 1993) could explain the dierences between human melanocytes and these melanoma cells in which TPA should act on other PKC isoforms leading to melanogenesis inhibition.
Noteworthy, in B16 melanoma cells, melanogenesis has been shown to be stimulated by cAMP elevating agents (Englaro et al., 1995) and U.V.B. (Oka and Ichihashi, 1996) indicating that PKC b is not absolutely required for the regulation of melanogenesis. However, these observations and our results do not exclude that the PKC b isoform is involved in melanogenesis up-regulation in human melanocytes.
Taken together, our data support the notion that PKC activation is not required for melanogenesis stimulation but is rather responsible for the inhibition of melanin synthesis evoked by TPA. The inhibitory eect of TPA is mainly observed in forskolin-treated cells. Indeed, we used sub-con¯uent cells and culture conditions favoring the cell growth. Under these conditions, we have a very low basal melanogenesis and a strong stimulation of melanogenesis by cAMP elevating agents, but it is dicult to measure the inhibition induced by TPA on the basal melanogenic activity. However, when we performed experiments on more con¯uent cells, with high basal pigmentation, we observed a clear inhibition of the basal melanogenesis by TPA (not shown).
In a second part of our report, we attempted to further investigate the mechanism by which TPA decreases the tyrosinase gene transcription. First, we have located the cis-acting element by which TPA exerts its eect. The eect of TPA on gene transcription is mainly mediated through AP1 transcription factor activation. However, deletions of three AP1 binding sites and mutation of a pseudo-AP1 site overlapping the M-box in the tyrosinase promoter did not change the responsiveness to TPA and forskolin. This shows that these elements of the tyrosinase promoter are not targets for the TPA action. The eect of TPA is still observed on the shortest construct (pTYRO-0.1) that contains the tissue-speci®c element and that responds to cAMP, suggesting that the same element and the same transcription factor might be involved in these regulatory processes.
Microphthalmia gene controls melanocyte development and survival (Hodgkinson et al., 1993) . It also plays a crucial role in the control of the tissue-speci®c expression of the melanogenic genes (Ganss et al., 1994; Lowings et al., 1992; Yavuzer et al., 1995) . Further, in a previous study, we have shown that microphthalmia, through the binding to the M-box upstream from the TATA box, mediates the eect of cAMP on the tyrosinase promoter (Bertolotto et al., 1996) . Since TPA decreases the stimulation of melanogenesis induced by forskolin, we focused our attention on the eect of TPA on microphthalmia binding. Interestingly, we observed in nuclear extracts from cAMP-treated cells that a 3 h treatment with TPA strongly decreases the microphthalmia binding to the M-box. Since microphthalmia strongly stimulates the tyrosinase promoter transcriptional activity, this result explains the inhibitory eect of TPA on the tyrosinase gene transcription. Several hypothesis can be proposed to explain this eect of TPA on micro- Gel shift assays were performed using the 32 P labeled M-box and B16 nuclear extracts from control cells (Cont) or cells treated for 3 h with 20 mM forskolin (Fsk), 160 nM TPA or with both eectors. Binding reactions were performed in presence of 0.3 ml of pre-immune serum (lanes 1, 3, 5, 7 ) or with 0.3 ml of a speci®c anti-microphthalmia serum (lanes 2, 4, 6, 8) phthalmia. TPA either decreases microphthalmia expression or induces post-translational modi®cations of microphthalmia that impair its binding to the Mbox of the tyrosinase promoter. Studies have been undertaken to elucidate the mechanisms by which TPA inhibits microphthalmia binding.
Noteworthy, Western blot experiments showed that a 48 h treatment with TPA lead to a dramatic depletion in PKC a, g and y (not shown). Further, the inhibition of melanogenesis by TPA was observed after 48 h. In no circumstances the inhibition of melanogenesis must be correlated with PKC down regulation. Indeed, we measured melanogenesis after 48 h because it is needed to accumulate enough tyrosinase to measure the changes in its activity and expression, but the stimulation of tyrosinase gene expression has been triggered by a much earlier event, that is probably the binding of microphthalmia to the M-box of the tyrosinase promoter (Bertolotto et al., 1996) . Interestingly; the stimulation of microphthalmia binding to the M-box by forskolin and the inhibition of this eect by TPA were observed after 3 h demonstrating that TPA eect has been elicited by an early event, before PKC down regulation. This observation clearly indicates that PKC activation is responsible for the inhibition of microphthalmia binding and of melanogenesis.
In summary, the compelling evidences gathered in the present report demonstrate that TPA, through PKC activation, represses the tyrosinase gene transcription thus inhibiting melanogenesis. The eect of TPA is clearly explained by the inhibition of microphthalmia binding to the M-box of the tyrosinase promoter. These results greatly improve our fundamental understanding of the role of PKC in the regulation of melanoma cells dierentiation and strengthen the pivotal role of microphthalmia in the control of melanogenesis.
Materials and methods

Materials
Forskolin, 12-O-tetradecanoly-13-acetate (TPA) and 4-(2-aminoethyl)-benzene-sulfonyl¯uoride (AEBSF), aprotinin leupeptin and synthetic melanins were purchased from Sigma Chem. Co. Dulbecco's modi®ed Eagles medium (DMEM), trypsin and lipofectamine reagent were from GIBCO. Fetal calf serum (FCS) was from Hyclone and PKC inhibitors, RO 8220, RO 3282 and staurosporine were from Calbiochem. Polyclonal rabbit antiserum to tyrosinase (PEP 7) was kindly provided by Dr V Hearing (Bethesda, USA) and peroxidase-conjugated anti-rabbit antibodies were from Dakopatts. Synthetic oligonucleotides were from Oligo express.
Cell cultures
B16/F10 murine melanoma cells were grown at 378C under 5% CO 2 in DMEM supplemented with 7% FCS and penicillin/streptomycin (100 U/ml/50 mg/ml).
Melanin content determination
Cells were seeded in 6-well dishes and exposed during the indicated times to the dierent eectors. Then, cells were solubilized in 100 ml 0.5 M NaOH. The samples were incubated at 658C for 1 h to solubilize the melanin. Absorbance at 405 nm was compared with a standard curve of known concentrations of fungal melanin prepared in a ®nal NaOH concentration of 0.5 M. The melanin content was corrected by the total amount of protein of the dish.
Western blot assays
B16 mouse melanoma cells were grown in 6-well dishes with or without 20 mM forskolin (Fsk), 160 nM TPA, 70 nM staurosporine (St), 250 nM RO 8220 or 500 nM RO 3282 for 48 h. Then, cells were lysed in phosphate buer, pH 6.8 containing 1% (w/v) Triton X-100, 5 mg/ml leupeptin, 1 mM AEBSF and 100 IU/ml aprotinin. Proteins (30 mg) were separated on 7.5% SDS-polyacrylamide gel and transferred to a nitrocellulose membrane. Tyrosinase protein was detected with the PEP7 antibody at a 1/3000 dilution in saturation buer and with a secondary peroxidase-conjugated anti-rabbit antibody at a 1/3000 dilution. Proteins were visualized with the ECL system from Amersham.
Construction of the reporter plasmids, transfection and luciferase assays
The reporter plasmids containing a 2.2 kb, 1.3 kb and a 0.1 kb fragment of the mouse tyrosinase promoter (respectively pTYRO-2.2; 72236/+59, pTYRO-1.3; 71317/+59 and pTYRO-0.1; 7126/+59) were described in our previous study (Bertolotto et al., 1996) . pTYRO-0.1DAP1 was obtained using the Transformer TM sitedirected mutagenesis kit (Clontech) by mutation of the pseudo-AP1 site located between 7120 and 7116 base pairs upstream from the initiation start site of pTYRO-0.1 Mutation of the construct was veri®ed by plasmid sequencing.
B16 melanoma cells were seeded in 24-well dishes and transient transfections were performed the following day using 2 ml of lipofectamine and 0.3 to 0.5 mg of total plasmid DNA in a 200 ml ®nal volume as indicated in ®gure legends. 0.05 mg pCMVbGal was transfected with the test plasmids to control the variability in transfection eciency. Forty-eight hours after transfection, soluble extracts were harvested in 50 ml of lysis buer and assayed for luciferase and b-galactosidase activities. All transfections were repeated at least ®ve times using dierent plasmid preparations.
Nuclear extracts and gel mobility shift assays B16 cells were incubated with the dierent eectors and the nuclear extracts were prepared essentially as previously described (Dignam et al., 1983) except that phosphatase inhibitors were added to the nuclear extraction buer. Double-stranded synthetic M-box, 5'-GAAAAAGT-CATGTGCTTTGCAGAAGA-3' was g 32 P end-labeled using T4 polynucleotide kinase. 5 mg of nuclear proteins were preincubated in a binding buer containing 10 mM Tris pH 7.5, 100 mM NaCl, 1 mM DTT, 1 mM EDTA, 4% glycerol, 80 mg/ml of salmon sperm DNA, 0.1 mg poly (dIdC), 10% FCS, 2 mM MgCl 2 and 2 mM spermidine for 15 min on ice. Then, 30 000 ± 50 000 c.p.m. of 32 P labeled probe were added to the binding reaction for 10 min at room temperature. DNA-protein complexes were resolved by electrophoresis on a 4% polyacrylamide gel (37.5 : 1 Acrylamide-Bisacrylamide) in TBE buer (22.5 mM Trisborate, 0.5 mM EDTA, pH 8) for 2 h at 150 V. For supershift assays, 0.3 ml of the anti-microphthalmia antibodies (Bertolotto et al., 1996) were preincubated with nuclear extracts in the binding reaction buer before adding the labeled probe.
Abbreviations TPA, 12-O-tetradecanoylphorbol-13-acetate; Fsk, forskolin; a-MSH, a-melanocyte stimulating hormone; IBMX, isobutylmethylxanthine; PKC, protein kinase C; TRP, tyrosine related protein; DOPA, 3,4-dihydroxyphenylalanine; b-HLH LZ, basic-helix ± loop ± helix leucine zipper; AEBSF, 4-(2-aminoethyl)benzene sulfonyl¯uoride; DTT, dithiothreitol; EDTA, ethylenediamine tetraacetic acid; poly (dIdC) polydeoxylinosinic deoxycytidylic acid.
